Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role

被引:23
作者
Bozzo, Jordi [1 ]
Jorquera, Juan I. [2 ]
机构
[1] Grifols, Global Sci & Med Affairs, Avi Generalitat 152-158, Barcelona 08174, Spain
[2] Grifols, Res & Dev, Biosci Ind Grp, Barcelona, Spain
关键词
Emerging disease; immunoglobulin; infection; outbreak; plasma; serum; RESPIRATORY SYNCYTIAL VIRUS; INTRAVENOUS IMMUNE GLOBULIN; CLOSTRIDIUM-DIFFICILE DIARRHEA; RENAL-TRANSPLANT RECIPIENTS; CONGO HEMORRHAGIC-FEVER; DISSEMINATED ADENOVIRUS INFECTION; ANTIBODY-DEPENDENT ENHANCEMENT; TICK-BORNE ENCEPHALITIS; BIRTH-WEIGHT INFANTS; HEPATITIS-A VACCINE;
D O I
10.1080/14787210.2017.1328278
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Pooled human immunoglobulins (IGs) are prepared from plasma obtained from healthy donors as a concentrated antibody-containing solution. In addition, high-titer IGs (hyperimmune) against a specific pathogen can be obtained from vaccinated or convalescing donors. Currently, IGs can be used for the treatment of a variety of infections for which no specific therapy exists or that remain difficult to treat. Moreover, the recent pathogen outbreaks for which there is no approved treatment have renewed attention to the role of convalescent plasma and IGs.Areas covered: In this review, a historical perspective of the use of sera and IGs in humans as anti-infective agents (any viral, bacterial, parasitic infection), excluding immunodeficient patients, is presented from early development to the latest clinical studies. A Medline search was conducted to examine the peer-reviewed literature, with no date limits.Expert commentary: Human pooled plasma-derived IG products benefit from the polyclonal response of every individual donor and from the interindividual variability in such response. The trend to increased availability of vaccines for infectious diseases also opens new potential applications of hyperimmune IGs for emerging or re-emerging infectious diseases (e.g.: Ebola, Zika, Dengue), for the prevention and treatment in the general population, healthcare personnel and caregivers.
引用
收藏
页码:585 / 604
页数:20
相关论文
共 196 条
[1]  
Abougergi Marwan S, 2010, J Hosp Med, V5, pE1, DOI 10.1002/jhm.542
[2]  
Agarwal M, 1998, NATL MED J INDIA, V11, P209
[3]  
Agostini G, 1992, Clin Ter, V141, P11
[4]   The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries [J].
Aguiar, Maira ;
Stollenwerk, Nico ;
Halstead, Scott B. .
PLOS NEGLECTED TROPICAL DISEASES, 2016, 10 (12)
[5]   Intrapartum mucosal exposure to human immunodeficiency virus type 1 (HIV-1) of infants born to HIV-1-infected mothers correlates with maternal plasma virus burden [J].
Ait-Khaled, M ;
Lyall, EGH ;
Stainsby, C ;
Taylor, GP ;
Wright, A ;
Weber, JN ;
McClure, MO ;
Tudor-Williams, G .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (04) :1097-1100
[6]   Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients [J].
Alexander, Bryan T. ;
Hladnik, Lindsay M. ;
Augustin, Kristan M. ;
Casabar, Ed ;
McKinnon, Peggy S. ;
Reichley, Richard M. ;
Ritchie, David J. ;
Westervelt, Peter ;
Dubberke, Erik R. .
PHARMACOTHERAPY, 2010, 30 (06) :554-561
[7]  
AlHemsi B, 1996, CLIN TRANSPLANT, V10, P668
[8]   Toxic epidermal necrolysis associated with acute infection by Mycoplasma pneumoniae [J].
Amelia Calvano, Roberta ;
Florencia Scacchi, Maria ;
Maria Sojo, Magdalena ;
Marta Diaz, Silvia ;
Ines Volonteri, Victoria ;
Claudia Giachetti, Ana .
ARCHIVOS ARGENTINOS DE PEDIATRIA, 2013, 111 (01) :E24-E27
[9]  
AMER J, 1963, PEDIATRICS, V32, P4
[10]   Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens [J].
Anderson, Robert D. ;
Chinnakotla, Srinath ;
Guo, Linsheng ;
Perrillo, Robert P. ;
Klintmalm, Goeran B. ;
Davis, Gary L. .
CLINICAL TRANSPLANTATION, 2007, 21 (04) :510-517